YenZym Antibodies

Executive Summary

YenZym Antibodies is a privately held custom antibody service provider based in San Diego, California, founded in 2009. The company specializes in the production of polyclonal antibodies against post-translational modifications (PTMs), including phospho-specific, ubiquitin-specific, sumo-specific, methyl-specific (me1, me2, me3), splice-junction-specific, and neo-epitope-specific antibodies. By focusing on these challenging targets, YenZym enables researchers to study critical cellular processes such as signaling, degradation, and epigenetic regulation. The company's services cater to academic, pharmaceutical, and biotechnology clients seeking high-quality, customized reagents for their specific research needs. As the demand for PTM-specific antibodies grows with advances in proteomics and personalized medicine, YenZym is well-positioned to capture a niche market. The company's expertise in custom production allows it to offer tailored solutions that large catalog suppliers may not provide. However, as a small private entity with limited public information, its growth trajectory and financial stability are less visible. The company's ability to scale operations, form strategic partnerships, and innovate in recombinant PTM antibodies will be key to its long-term success. Overall, YenZym represents a specialized tool provider in the life sciences ecosystem, with opportunities for expansion as PTM research continues to expand.

Upcoming Catalysts (preview)

• Q3 2026Launch of Expanded PTM Antibody Catalog Including New Modifications70% success
• Q4 2026Strategic Partnership with Major Research Institution or Biotech50% success
• Q2 2027Introduction of Recombinant Monoclonal PTM Antibodies60% success